<DOC>
	<DOC>NCT01983722</DOC>
	<brief_summary>Expanded access to Stiripentol for patients with Dravet Syndrome.</brief_summary>
	<brief_title>Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome</brief_title>
	<detailed_description>This is a treatment plan, and therefore patients will be monitored according to clinical standard of care.</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsies, Myoclonic</mesh_term>
	<mesh_term>Stiripentol</mesh_term>
	<criteria>6 months and older Diagnosis of Dravet Syndrome with intractable seizures Hypersensitivity to the active substance or to any of the excipients Past history of psychoses in the form of episodes of delirium Impaired hepatic and/or renal function, defined as creatinine &gt;2 and/or transaminase &gt;4xULN</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>